PDF(Pubmed)
Abstract：
Inflammatory bowel diseases are considered immune disorders with a complex genetic architecture involving constantly changing endogenous and exogenous factors. The rapid evolution of genomic technologies and the emergence of newly discovered molecular actors are compelling the research community to reevaluate the knowledge and molecular processes. The human intestinal tract contains intestinal human microbiota consisting of commensal, pathogenic, and symbiotic strains leading to immune responses that can contribute and lead to both systemic and intestinal disorders including IBD. In this review, we attempted to highlight some updates of the new IBD features related to genomics, microbiota, new emerging therapies and some major established IBD risk factors.
摘要：
炎症性肠病被认为是具有复杂遗传结构的免疫性疾病，涉及不断变化的内源性和外源性因素。基因组技术的快速发展和新发现的分子行动者的出现迫使研究界重新评估知识和分子过程。人类肠道含有肠道人类微生物群，由共生，致病性,以及导致免疫反应的共生菌株，这些免疫反应可能有助于并导致包括IBD在内的全身性和肠道疾病。在这次审查中,我们试图强调与基因组学相关的新IBD特征的一些更新，微生物群,新的新兴疗法和一些主要的已建立的IBD危险因素。
